Update on toll-like receptor-directed therapies for human disease - PubMed (original) (raw)

Review

Update on toll-like receptor-directed therapies for human disease

Kevin Tse et al. Ann Rheum Dis. 2007 Nov.

Abstract

Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Medzhitov R, Janeway C A., Jr Decoding the patterns of self and nonself by the innate immune system. Science 2002296298–300. - PubMed
    1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006124783–801. - PubMed
    1. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 20045971–974. - PubMed
    1. Rifkin I R, Leadbetter E A, Busconi L, Viglianti G, Marshak‐Rothstein A. Toll‐like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 200520427–42. - PubMed
    1. Ishii K J, Akira S. Innate immune recognition of nucleic acids: beyond toll‐like receptors. Int J Cancer 2005117517–523. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources